Leiomyosarcoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Leiomyosarcoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Trabectedin alone versus Trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/ Wed, 29 Apr 2026 14:59:55 +0000 https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/ This clinical trial studies a treatment for soft tissue sarcoma, a type of cancer that develops in soft tissues like muscles and fat. The study focuses on patients whose cancer has spread to other parts of the body (metastatic) or who did not respond well to previous treatments. The trial compares two treatment approaches: one using only trabectedin (a chemotherapy medication) and another combining trabectedin with tTF-NGR (an experimental drug).

The study aims to determine if adding tTF-NGR to standard trabectedin treatment helps keep the cancer under control for a longer time. Both medications are given through an intravenous infusion directly into the bloodstream. The experimental drug tTF-NGR is designed to concentrate the chemotherapy medication inside the tumor.

During the study, participants receive treatment for up to 360 days. Some patients will receive only trabectedin, while others will receive both trabectedin and tTF-NGR. Regular medical examinations and imaging tests will be performed to monitor how the cancer responds to the treatment. The study focuses on patients whose tumors show a specific characteristic called CD13 positivity, which is determined through laboratory testing.

]]> Study on the Effectiveness and Safety of INT230-6 (Vinblastine Sulfate, Cisplatin) for Adults with Metastatic Soft Tissue Sarcomas https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-int230-6-vinblastine-sulfate-cisplatin-for-adults-with-metastatic-soft-tissue-sarcomas/ Wed, 29 Apr 2026 14:59:28 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-int230-6-vinblastine-sulfate-cisplatin-for-adults-with-metastatic-soft-tissue-sarcomas/ This clinical trial is focused on studying the effectiveness and safety of a new treatment called INT230-6 for patients with certain types of soft tissue sarcomas. Soft tissue sarcomas are a group of cancers that begin in the tissues that connect, support, or surround other structures and organs of the body. The specific types of sarcomas being studied include liposarcoma, undifferentiated pleomorphic sarcoma, and leiomyosarcoma. The treatment INT230-6 is a combination of two substances, vinblastine sulfate and cisplatin, which are administered directly into the tumor.

The purpose of the study is to compare the new treatment, INT230-6, with the standard care currently used in the United States for these types of sarcomas. Participants in the study will receive either the new treatment or the standard care, which may include other medications such as Halaven, Trabectedin, or Pazopanib. The study will last for a period of up to 24 months, during which the participants’ health and response to the treatment will be closely monitored.

This trial aims to provide valuable information on whether INT230-6 can improve the overall survival of patients with these challenging types of cancer. The study will also look at the side effects and overall quality of life of the participants during the treatment period. By participating in this study, researchers hope to find more effective ways to treat soft tissue sarcomas and improve outcomes for patients in the future.

]]> Study Comparing Trabectedin and Gemcitabine for Patients with Advanced or Metastatic Leiomyosarcoma After Chemotherapy https://clinicaltrials.eu/trial/study-comparing-trabectedin-and-gemcitabine-for-patients-with-advanced-or-metastatic-leiomyosarcoma-after-chemotherapy/ Wed, 29 Apr 2026 14:28:39 +0000 https://clinicaltrials.eu/trial/study-comparing-trabectedin-and-gemcitabine-for-patients-with-advanced-or-metastatic-leiomyosarcoma-after-chemotherapy/ This clinical trial is focused on studying a type of cancer called leiomyosarcoma, which can either spread to other parts of the body (metastatic) or grow in a specific area (locally advanced). The study is comparing two treatments: Trabectedin and Gemcitabine. Both medications are given as a solution through a vein, known as an infusion. The purpose of the study is to compare how well these treatments work in patients who have already received chemotherapy based on a drug called anthracycline.

Participants in the study will receive either Trabectedin or Gemcitabine. The study will observe how the cancer responds to these treatments over time. The main focus is on the growth modulation index (GMI), which is a way to measure how the cancer’s growth is affected by the treatment. A GMI greater than 1.33 is considered a positive sign in this type of study. The study will also look at other factors, such as how long patients live, how long they live without the cancer getting worse, and how safe and tolerable the treatments are.

The study will continue for a period of time, during which patients will be monitored regularly to assess the effectiveness and safety of the treatments. The goal is to gather information that could help improve treatment options for patients with advanced leiomyosarcoma. This study is part of ongoing research to find better ways to manage and treat this type of cancer.

]]> Study on the Effect of Chemotherapy with Ifosfamide, Dacarbazine, and Epirubicin Hydrochloride Before Surgery for Patients with High-Risk Retroperitoneal Sarcoma https://clinicaltrials.eu/trial/study-on-the-effect-of-chemotherapy-with-ifosfamide-dacarbazine-and-epirubicin-hydrochloride-before-surgery-for-patients-with-high-risk-retroperitoneal-sarcoma/ Wed, 29 Apr 2026 14:23:22 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-chemotherapy-with-ifosfamide-dacarbazine-and-epirubicin-hydrochloride-before-surgery-for-patients-with-high-risk-retroperitoneal-sarcoma/ This clinical trial is focused on studying the effects of chemotherapy before surgery in patients with a type of cancer called retroperitoneal sarcoma. This cancer occurs in the area behind the abdominal organs. The study specifically looks at two subtypes of this cancer: leiomyosarcoma and liposarcoma. The treatment being tested involves using chemotherapy drugs such as ifosfamide, dacarbazine, epirubicin hydrochloride, and doxorubicin hydrochloride. These drugs are given through a vein, which is known as intravenous use.

The purpose of the study is to see if giving chemotherapy before surgery can improve the chances of the cancer not coming back after surgery. Patients will be randomly assigned to receive either chemotherapy followed by surgery or surgery alone. The study will last for several years, and patients will be monitored for their health and any signs of cancer returning. The main focus is on how long patients remain free of cancer after treatment, which is called disease-free survival. Other aspects being studied include overall survival, the response of the cancer to the chemotherapy, and any side effects from the treatment.

Participants in the study will undergo various tests and procedures, including imaging tests like MRI and CT scans, to assess the size and spread of the cancer. These tests help doctors determine if the cancer can be surgically removed. The study aims to gather information that could help improve treatment strategies for patients with high-risk retroperitoneal sarcoma, potentially leading to better outcomes and quality of life.

]]>